Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

ABSTRACT:

Background

Quantifying pediatric immunologic recovery by highly active antiretroviral therapy (HAART) initiation at different CD4 percentage (CD4%) and age thresholds may inform decisions about timing of treatment initiation.

Methods

HIV-1-infected, HAART-naive children in Europe and the Americas were followed from 2002 through 2009 in PENPACT-1. Data from 162 vertically infected children, with at least World Health Organization "mild" immunosuppression and CD4% <10th percentile, were analyzed for improvement to a normal CD4% (≥10th percentile) within 4 years after HAART initiation. Data from 209 vertically infected children, regardless of immune status, were analyzed for CD4% outcomes at 4 years and viral failure within 4 years.

Results

Seventy-two percent of baselin

SUBMITTER: Yin DE 

PROVIDER: S-EPMC4179097 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature